UK's NICE rec­om­mends against cov­er­age for As­traZeneca and Dai­ichi's breast can­cer drug En­her­tu over cost-ef­fec­tive­ness

The UK’s Na­tion­al In­sti­tute for Health and Care Ex­cel­lence (NICE) said Tues­day that it won’t rec­om­mend cov­er­age of As­traZeneca and Dai­ichi Sankyo’s can­cer drug En­her­tu for treat­ing ad­vanced HER2-low breast can­cer in adults.

NICE said that while NHS Eng­land has been ne­go­ti­at­ing with the com­pa­ny over the price of the drug since De­cem­ber, they weren’t able to reach an agree­ment. It’s not a huge sur­prise — NICE’s draft guid­ance in Sep­tem­ber said it didn’t rec­om­mend En­her­tu be­cause of doubts around its cost-ef­fec­tive­ness.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER